Alnylam Pharmaceuticals reported $-274673000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Arrowhead Research ARWR:US $ -72.05M 116.41M
Biomarin Pharmaceutical BMRN:US $ 34.85M 8.66M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
IONIS PHARMACEUT IONS:US $ -103M 39M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Novartis NVS:US $ 4129M 217M
Ptc Therapeutics PTCT:US $ -148.7M 26.8M
Regulus Therapeutics RGLS:US $ -7.26M 0.54M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Takeda 4502:JP Y 155473M 209520M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M
Xencor XNCR:US $ -33.98M 57.57M